Standard BioTools And 2 Other Penny Stocks Executives Are Buying
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 28 2024
0mins
Source: Benzinga
Insider Transactions Overview: Recent insider purchases in penny stocks include CalciMedica's CEO buying 1,000 shares at $4.19, Zevia PBC's director acquiring 13,705 shares at $1.09, and Ault Alliance's executive chairman purchasing 3,800 shares at $0.23, reflecting varying levels of confidence amid recent financial performances.
Company Profiles: CalciMedica focuses on therapies for inflammatory diseases, Zevia PBC offers zero-calorie beverages, and Ault Alliance, soon to be renamed Hyperscale Data, operates a Bitcoin mining data center and supports various industries.
Analyst Views on CALC
Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.280
Low
20.00
Averages
20.00
High
20.00
Current: 5.280
Low
20.00
Averages
20.00
High
20.00
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
